BEAM on Nasdaq

Beam Therapeutics

Logo: Beam Therapeutics, Public domain, via Wikimedia Commons⁴

American biotechnology company

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing.³ From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

Compare with Monte Rosa Therapeutics, Atara Biotherapeutics, Inc. or Acorda Therapeutics, or pick any stock.

TickerBEAM on Nasdaq¹
Industrybiotechnology¹
HeadquartersDE¹
Websitewww.beamtx.com
Incorporated inDE⁵
Business address26 Landsdowne Street, Cambridge, Ma 02139⁵
Filer categoryLarge accelerated filer⁵

See how the biggest companies compare on our leaderboards

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-274.6%Operating margin⁷

-57.2%Net margin⁷

120.0%Revenue growth, 2025⁷

-6.5%Return on equity⁷

-$360.0MFree cash flow⁷

Where the money goes

Where each dollar of revenue went, fiscal 2025

Research and development

Research and development100¢$409.6M

Out of $139.7M in revenue.⁷ The company lost money this year.

Financial statements

Revenue⁸⁹¹⁰¹¹⁷$139.7M in 2025+776250% since 2019

Operating income⁸⁹¹⁰¹¹⁷-$383.7M in 2025+411% since 2019

Net income⁸⁹¹⁰¹¹⁷-$80.0M in 2025+2% since 2019

Every line of the income statement in the latest annual report, as filed.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
License and collaboration revenue	$139.7M	$63.5M	$377.7M
Research and development	$409.6M	$367.6M	$437.4M
General and administrative	$113.8M	$111.5M	$116.8M
Total operating expenses	$523.4M	$479.1M	$554.2M
Loss from operations	-$383.7M	-$415.6M	-$176.5M
Change in fair value of derivative liabilities	$700.0K	$2.3M	$7.5M
Change in fair value of non-controlling equity investments	$3.9M	-$14.1M	-$18.6M
Change in fair value of contingent consideration liabilities	$180.0K	$1.6M	$9.7M
Gain on sale of equity method investment	$255.1M
Interest and other income (expense), net	$43.7M	$49.1M	$46.7M
Total other income (expense)	$303.7M	$38.9M	$45.3M
Net loss before income taxes	-$80.0M	-$376.7M	-$131.2M
Provision for income taxes	$0	-$39.0K	-$1.4M
Net loss	-$80.0M	-$376.7M	-$132.5M
Unrealized gain (loss) on marketable securities	$432.0K	$75.0K	$3.0M
Comprehensive loss	-$79.6M	-$376.7M	-$129.5M
Net loss per common share, basic	-$0.81	-$4.58	-$1.72
Net loss per common share, diluted	-$0.81	-$4.58	-$1.72
Weighted - average common shares outstanding, basic	98.9M shares	82.3M shares	77.2M shares
Weighted - average common shares outstanding, diluted	98.9M shares	82.3M shares	77.2M shares

Total assets¹⁴⁸⁹¹⁰¹¹⁷$1.5B in 2025+849% since 2019

Total liabilities¹⁴⁸⁹¹⁰¹¹⁷$242.8M in 2025+340% since 2019

Shareholders’ equity⁹¹⁰¹¹⁷$1.2B in 2025

Cash⁸⁹¹⁰¹¹⁷$294.9M in 2025+692% since 2019

Every line of the balance sheet in the latest annual report, as filed.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$294.9M	$282.0M	$435.9M
Marketable securities	$950.3M	$568.8M
Prepaid expenses and other current assets	$23.5M	$27.4M
Total current assets	$1.3B	$878.1M
Property and equipment, net	$104.5M	$111.4M
Restricted cash	$6.7M	$8.1M	$8.7M
Operating lease right-of-use assets	$100.7M	$104.9M
Other assets	$634.0K	$1.3M
Total assets	$1.5B	$1.1B
Accounts payable	$10.2M	$3.9M
Accrued expenses and other current liabilities	$55.3M	$47.5M
Current portion of derivative liabilities	$7.7M	$8.4M
Current portion of deferred revenue	$6.7M	$108.9M
Current portion of lease liability	$14.4M	$13.5M
Current portion of contingent consideration liabilities	$2.7M
Total current liabilities	$96.9M	$182.1M
Long-term lease liability	$139.8M	$148.0M
Long-term portion of contingent consideration liabilities	$6.0M	$1.1M
Long-term portion of deferred revenue	$0	$33.2M
Long-term portion of derivative liabilities	$0	$5.4M
Other liabilities	$173.0K	$504.0K
Total liabilities	$242.8M	$370.3M
Common stock, $0.01 par value; 250,000,000 shares authorized, 101,748,962 and 83,633,069 issued and outstanding at December 31, 2025 and December 31, 2024, respectively	$1.0M	$836.0K
Additional paid-in capital	$2.9B	$2.3B
Accumulated other comprehensive (loss) income	$1.1M	$679.0K
Accumulated deficit	-$1.6B	-$1.6B
Total stockholders' equity	$1.2B	$733.5M	$981.3M
Total liabilities and stockholders' equity	$1.5B	$1.1B
Preferred stock, par or stated value per share	$0.01	$0.01
Preferred stock, shares authorized	25.0M shares	25.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par or stated value per share	$0.01	$0.01
Common stock, shares authorized	250.0M shares	250.0M shares
Common stock, shares issued	101.7M shares	83.6M shares
Common stock, shares outstanding	101.7M shares	83.6M shares

Cash from operations⁸⁹¹⁰¹¹⁷-$345.1M in 2025+379% since 2019

Capital spending⁸⁹¹⁰¹¹⁷$14.9M in 2025+19% since 2019

Free cash flow⁸⁹¹⁰¹¹⁷-$360.0M in 2025+326% since 2019

Every line of the cash flow in the latest annual report, as filed.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Net loss	-$80.0M	-$376.7M	-$132.5M
Depreciation and amortization	$22.3M	$21.9M	$20.0M
Amortization of investment discount (premiums)	-$16.0M	-$22.8M	-$29.7M
In-process research and development charge	$14.5M	$0	$0
Stock-based compensation expense	$94.2M	$120.7M	$98.6M
Change in operating lease right-of-use assets	$10.4M	$9.7M	$9.5M
Change in fair value of derivative liabilities	-$700.0K	-$2.3M	-$7.5M
Change in fair value of contingent consideration liabilities	-$180.0K	-$1.6M	-$9.7M
Change in fair value of non-controlling equity investments	-$3.9M	$14.1M	$18.6M
Realized loss (gain) on sale of marketable securities	$399.0K	$0	$0
Gain on sale of equity method investment	-$255.1M	$0	$0
Prepaid expenses and other current assets	$4.5M	-$5.3M	-$6.6M
Accounts payable	$6.0M	$1.8M	-$7.6M
Accrued expenses and other liabilities	$7.7M	-$57.7M	$67.7M
Operating lease liabilities	-$13.5M	-$13.0M	-$10.2M
Deferred revenue	-$135.4M	-$36.5M	-$159.6M
Other long-term liabilities	-$330.0K	$473.0K	-$194.0K
Net cash provided by (used in) operating activities	-$345.1M	-$347.2M	-$149.2M
Purchases of property and equipment	-$14.9M	-$8.9M	-$33.7M
Purchases of marketable securities	-$1.2B	-$486.4M	-$984.3M
Maturities of marketable securities	$842.5M	$680.4M	$1.1B
Proceeds from sale of marketable securities	$5.7M	$0	$0
Cash paid for acquisition, net	-$78.0K	$0	$0
Proceeds from sale of equity method investment	$255.1M	$0	$0
Net cash provided by (used in) investing activities	-$121.4M	$185.0M	$71.8M
Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs	$470.5M	$0	$235.9M
Proceeds from issuances of stock under ESPP	$2.8M	$2.6M	$3.0M
Equipment financings, net	$0	-$485.0K	-$2.3M
Proceeds from exercise of stock options	$4.8M	$5.6M	$6.1M
Proceeds from private stock issuance	$0	$0	$33.6M
Net cash provided by (used in) financing activities	$478.0M	$7.7M	$276.4M
Net change in cash, cash equivalents and restricted cash	$11.5M	-$154.5M	$199.1M
Cash paid for interest	$0	$32.0K	$160.0K
Property and equipment additions in accounts payable and accrued expenses	$1.3M	$834.0K	$1.4M
Operating lease liabilities arising from obtaining right-of-use assets	$6.2M	-$1.6M	$3.9M
Contingent consideration liabilities assumed in acquisition	$7.7M	$0	$0
Fair value of equity instruments issued in connection with acquisition	$6.7M	$0	$0

Compare Beam Therapeutics with another company

The story

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang. Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.

In 2026 clinical trial results were published on Beam's investigational medicine, ristoglogene autogetemcel, a CRISPR-based gene therapy for treatment of sickle cell disease.

From Wikipedia’s article on Beam Therapeutics, shared under CC BY-SA 4.0.⁶

Former names

Beam Therapeutics Inc.Aug 9, 2018 to Oct 2, 2026⁵

Recent filings

Oct 2, 20264
Sep 25, 20264
Aug 14, 2026SCHEDULE 13G/A
Aug 13, 2026SCHEDULE 13G/A
Aug 4, 20268-K
Aug 4, 202610-Q
Jul 29, 20264
Jul 27, 2026144
Jul 2, 20264
Jul 1, 20264
Jun 30, 2026144
Jun 29, 20264
Jun 29, 2026144
Jun 22, 20264
Jun 8, 20268-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.²

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataBeam Therapeutics on Wikidata
2
SEC EDGARBeam Therapeutics filings on SEC EDGAR
3
WikipediaBeam Therapeutics on Wikipedia
4
Wikimedia CommonsBeam Therapeutics logo by Beam Therapeutics, Public domain
5
SEC EDGARBeam Therapeutics filings on SEC EDGAR
6
WikipediaBeam Therapeutics on Wikipedia (revision used)
7
SEC EDGARBeam Therapeutics 10-K for fiscal 2025
8
SEC EDGARBeam Therapeutics 10-K for fiscal 2019
9
SEC EDGARBeam Therapeutics 10-K for fiscal 2020
10
SEC EDGARBeam Therapeutics 10-K for fiscal 2021
11
SEC EDGARBeam Therapeutics 10-K for fiscal 2022
12
SEC EDGARBeam Therapeutics 10-Q for fiscal 2026
13
SEC EDGARBeam Therapeutics 10-Q for fiscal 2026
14
SEC EDGARBeam Therapeutics 10-K for fiscal 2019